A study investigating intrathecal antibody responses during of Natalizumab treatment associated with natalizumab-associated progressive multifocal leukoencephalopathy (PML) and progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS) in patients with multiple sclerosis
Latest Information Update: 27 Feb 2016
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
Most Recent Events
- 27 Feb 2016 New trial record